Current Challenges in Developing Biosimilars

The development of biologics necessitate overcoming ton several challenges. With initial steps of ideas of biologics, their issues, necessities for early clinical developments it's a great deal required that correct scientific and strategic approaches area unit taken for the winning development of follow-on-biologics. Moreover, the requirement for overcoming the challenges continues within the late clinical steps, drug safety factors and labelling needs. Conjointly it's a lot of needed currently to develop a drug product in accordance to quality intentionally (QbD).This monetary unit biosimilars conference can explore the multiple sides of current challenges in Biosimilars development. This biosimilars conference can specialise in multiple aspects of biosimilars development to with success deliver safe, potential and efficacious life product to the market.

  • Biopharmaceuticals development
  • Quality by Design for Biologics and Biosimilars
  • Implimentation of the BPCI Act
  • Advertising, promotion and labelling essentials
  • Unique considerations for biologics
  • Comparability for biologics
  • Drug safety essentials
  • Late clinical development essentials
  • Early clinical development essentials
  • Biologics in genetic disorders
  • Biopharmaceuticals development

    Related Conference of Current Challenges in Developing Biosimilars

    November 27-27, 2021

    Drug Formulation Bioavailability 2021

    London, UK
    February 07-08, 2022

    World Congress on Pharmaceutical Chemistry

    Paris, France

    Current Challenges in Developing Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in